Anderberg UM, Marteinsdottir I, von Knorring L (2000) Citalopram in patients with fibromyalgia – a randomized, double-blind, placebo-controlled study. Eur J Pain 4: 27–35PubMedCrossRefGoogle Scholar

Arnold LM, Hess EV, Hudson JI et al. (2002) A randomized, placebo-controlled, double-blind, flexible-dose study of fluoxetine in the treatment of women with fibromyalgia. Am J Med 112: 191–197PubMedCrossRefGoogle Scholar

Arnold LM, Keck PE jr, Welge JA (2000) Antidepressant treatment of fibromyalgia. A meta-analysis and review. Psychosomatics 41: 104–113PubMedCrossRefGoogle Scholar

Arnold LM, Lu Y, Crofford LJ et al. (2004) A double-blind, multicenter trial comparing duloxetine with placebo in the treatment of fibromyalgia patients with or without major depressive disorder. Arthritis Rheum 50: 2974–2984PubMedCrossRefGoogle Scholar

Arnold LM, Rosen A, Pritchett YL et al. (2005) A randomized, double-blind, placebo-controlled trial of duloxetine in the treatment of women with fibromyalgia with or without major depressive disorder. Pain 119: 5–15PubMedCrossRefGoogle Scholar

Ataoğlu S, Ataoğlu A, Erdoğan F et al. (1997) Comparison of paroxetine, amitriptyline in the treatment of fibromyalgia. Turk J Med Sci 27: 535–539Google Scholar

Backman E, Bengtsson A, Bengtsson M et al. (1988) Skeletal muscle function in primary fibromyalgia. Effect of regional sympathetic blockade with guanethidine. Acta Neurol Scand 77: 187–191PubMedCrossRefGoogle Scholar

Bengtsson M, Bengtsson A, Jorfeldt L (1989) Diagnostic epidural opioid blockade in primary fibromyalgia at rest and during exercise. Pain Clin 39: 171–180Google Scholar

Bennett RM, Clark SC, Walczyk J (1998) A randomized, double-blind, placebo-controlled study of growth hormone in the treatment of fibromyalgia. Am J Med 104: 227–231PubMedCrossRefGoogle Scholar

Bennett RM, Gatter RA, Campbell SM et al. (1988) A comparison of cyclobenzaprine and placebo in the management of fibrositis. A dou-ble-blind controlled study. Arthritis Rheum 31: 1535–1542PubMedCrossRefGoogle Scholar

Bennett RM, Jones J, Turk DC et al. (2007) An internet survey of 2,596 people with fibromyalgia. BMC Musculoskelet Disord 8: 27PubMedCrossRefGoogle Scholar

Bennett RM, Kamin M, Karim R et al. (2003) Tramadol and acetaminophen combination tablets in the treatment of fibromyalgia pain: a double-blind, randomized, placebo-controlled study. Am J Med 114: 537–545PubMedCrossRefGoogle Scholar

Bennett RM, Schein J, Kosinski MR et al. (2005) Mpact of fibromyalgia pain on health-related quality of life before and after treatment with tramadol/acetaminophen. Arthritis Rheum 53: 519–527PubMedCrossRefGoogle Scholar

Bentsson A, Bengtsson M (1988) Regional sympathetic blockade in primary fibromyalgia. Pain Clin 33: 161–167Google Scholar

Bessette L, Carette S, Fosse A et al. (1998) A placebo controlled crossover trial of subcutaneous salmon calcitonin in the treatment of patients with fibromyalgia. Scand J Rheumatol 27: 112–116PubMedCrossRefGoogle Scholar

Biasi G, Manca S, Manganelli S et al. (1998) Tramadol in the fibromyalgia syndrome: a controlled clinical trial versus placebo. Int J Clin Pharmacol Res 13–19Google Scholar

Bibolotti E, Borghi C, Pasculli E (1986) The management of fibrositis: a double-blind comparison of maprotiline (ludiomil), chlor-imipramine, and placebo. J Clin Trials 23: 269–280Google Scholar

Cantini F, Bellandi F, Niccoli L et al. (1994) Fluoxetin combined with cyclobenzaprine in the treatment of fibromyalgia. Minerva Med 85: 97–100PubMedGoogle Scholar

Çapaci K, Hepgüler S (2002) Comparison of the effect of amitriptyline and paroxetine in the treatment of fibromyalgia syndrome. Pain Clin 14: 223–228CrossRefGoogle Scholar

Carette S, Bell MJ, Reynolds WJ et al. (1994) Comparison of amitriptyline, cyclobenzaprine, and placebo in the treatment of fibromyalgia. A randomized, double-blind clinical trial. Arthritis Rheum 37: 32–40PubMedCrossRefGoogle Scholar

Carette S, McCain GA, Bell DA et al. (1986) Evaluation of amitriptyline in primary fibrositis. A double-blind, placebo-controlled study. Arthritis Rheum 29: 655–659PubMedCrossRefGoogle Scholar

Carette S, Oakson G, Guimont C et al. (1995) Sleep electroencephalography and the clinical response to amitriptyline in patients with fibromyalgia. Arthritis Rheum 38: 1211–1217PubMedCrossRefGoogle Scholar

Clark S, Tindall E, Bennett RM (1985) A double blind crossover trial of prednisone versus placebo in the treatment of fibrositis. J Rheumatol 12: 980–983PubMedGoogle Scholar

Crofford LJ, Rowbotham MC, Mease PJ et al. (2005) Pregabalin 1008–105 Study Group. Pregabalin for the treatment of fibromyalgia syndrome: results of a randomized, double-blind, placebo-controlled trial. Arthritis Rheum 52: 1264–1273PubMedCrossRefGoogle Scholar

Drewes HM (1991) Zopiclone in the treatment of sleep abnormalities in fibromyalgia. Scand J Rheumatol 20: 288–293PubMedCrossRefGoogle Scholar

Dwight MM, Arnold LM, O’Brien H et al. (1998) An open clinical trial of venlafaxine treatment of fibromyalgia. Psychosomatics 39: 14–17PubMedGoogle Scholar

Färber L, Stratz TH, Bruckle W et al. (2001) German Fibromyalgia Study Group. Short-term treatment of primary fibromyalgia with the 5-HT3-receptor antagonist tropisetron. Results of a randomized, double-blind, placebo-controlled multicenter trial in 418 patients. Int J Clin Pharmacol Res 21: 1–13PubMedGoogle Scholar

Finckh A, Berner IC, Aubry-Rozier B et al. (2005) A randomized controlled trial of de-hydroepiandrosterone in postmenopausal women with fibromyalgia. J Rheumatol 32: 1336–1340PubMedGoogle Scholar

Freedenfeld RN, Murray M, Fuchs PN et al. (2006) Decreased pain and improved quality of life in fibromyalgia patients treated with olanzapine, an atypical neuroleptic. Pain Pract 6: 112–118PubMedGoogle Scholar

Gendreau RM, Thorn MD, Gendreau JF et al. (2005) Efficacy of milnacipran in patients with fibromyalgia. J Rheumatol 32: 1975–1985PubMedGoogle Scholar

Ginsberg F, Joos E, Geczy J et al. (1998) A pilot randomized placebo-controlled study of pirlindole in the treatment of primary fibromyalgia. J Musculoskel Pain 6: 6–17CrossRefGoogle Scholar

Ginsberg F, Mancaux A, Joos E et al. (1996) A randomized placebo-controlled trial of sustained-release amitriptyline in primary fibromyalgia. J Musculoskel Pain 4: 37–47CrossRefGoogle Scholar

Giordano N, Geraci S, Santacroce C et al. (1999) Efficacy and tolerability of paroxetine in patients with fibromyalgia syndrome: a single-blind study. Curr Ther Res 60: 696–702CrossRefGoogle Scholar

Goldenberg D, Mayskiy M, Mossey C et al. (1996) A randomized, double-blind crossover trial of fluoxetine and amitriptyline in the treatment of fibromyalgia. Arthritis Rheum 39: 1852–1859PubMedCrossRefGoogle Scholar

Goldenberg DL, Felson DT, Dinerman H (1986) A randomized, controlled trial of amitriptyline and naproxen in the treatment of patients with fibromyalgia. Arthritis Rheum 29: 1371–1377PubMedCrossRefGoogle Scholar

Gonzalez-Viejo MA, Avellanet M, Hernandez-Morcuende MI (2005) A comparative study of fibromyalgia treatment: ultrasonography and physiotherapy versus sertraline treatment. Ann Readapt Med Phys 48: 610–615PubMedGoogle Scholar

Gronblad M, Nykanen J, Konttinen Y et al. (1993) Effect of zopiclone on sleep quality, morning stiffness, widespread tenderness and pain and general dis-comfort in primary fibromyalgia patients. A double-blind randomized trial. Clin Rheumatol 12: 186–191PubMedCrossRefGoogle Scholar

Gür A, Karakoç M, Nas K et al. (2002) Effects of low power laser and low dose amitriptyline therapy on clinical symptoms and quality of life in fibromyalgia: a single-blind, placebo-controlled trial. Rheumatol Int 22: 188–193PubMedCrossRefGoogle Scholar

Hannonen P, Malminiemi K, Yli-Kerttula U et al. (1998) A randomized, double-blind, placebo-controlled study of moclobemide and amitriptyline in the treatment of fibromyalgia in females without psychiatric disorder. Br J Rheumatol 37: 1279–1286PubMedCrossRefGoogle Scholar

Häuser W, Musial F, Kopp I et al. (2008) Methodische Grundlagen für die Entwicklung der Leitlinienempfehlungen (Methodenreport). Schmerz, im DruckGoogle Scholar

Häuser W, Wilhelm R, Klein W et al. (2006) Subjektive Krankheitsattributionen und Inanspruchnahme medizinischer Leistungen von Patienten mit Fibromyalgiesyndrom. Schmerz 20: 119–127PubMedCrossRefGoogle Scholar

Heymann RE, Helfenstein M, Feldman D (2001) A double-blind, randomized, controlled study of amitriptyline, nortriptyline and placebo in patients with fibromyalgia. An analysis of outcome measures. Clin Exp Rheumatol 19: 697–702PubMedGoogle Scholar

Holman AJ, Myers RR (2005) A randomized, double-blind, placebo-controlled trial of pramipexole, a dopamine agonist, in patients with fibromyalgia receiving concomitant medications. Arthritis Rheum 52: 2495–2505PubMedCrossRefGoogle Scholar

Hrycaj P, Stratz T, Mennet P et al. (1996) Pathogenetic aspects of responsiveness to ondansetron (5-hydroxytryptamine type 3 receptor antagonist) in patients with primary fibromyalgia syndrome – a preliminary study. J Rheumatol 23: 1418–1423PubMedGoogle Scholar

Isomeri R, Mikkelson M, Latikka P et al. (1993) Effects of amitriptyline and cardiovascukar fitness training on patients with primray fibromyalgia. J Musculoscelet Pain 253–260Google Scholar

Jacobsen S, Danneskiold-Samsoe B, Andersen RB (1991) Oral S-adenosylmethionine in primary fibromyalgia. Double-blind clinical evaluation. Scand J Rheumatol 20: 294–302PubMedCrossRefGoogle Scholar

Jaeschke R, Adachi J, Guyatt G et al. (1991) Clinical usefulness of amitriptyline in fibromyalgia: the results of 23 N-of-1 randomized controlled trials. J Rheumatol 18: 447–451PubMedGoogle Scholar

Janzen VD, Scudds RA (1997) Sphenopalatine blocks in the treatment of pain in fibromyalgia and myofascial pain syndrome. Laryngoscope 107: 1420–1422PubMedCrossRefGoogle Scholar

Kempenaers C, Simenon G, Vander Elst M et al. (1994) Effect of an antidiencephalon immune serum on pain and sleep in primary fibromyalgia. Neuropsychobiology 30: 66–72PubMedCrossRefGoogle Scholar

Kendall SA, Schaadt ML, Graff LB et al. (2004) No effect of antiviral (valacyclovir) treatment in fibromyalgia: a double blind, randomized study. J Rheumatol 31: 783–784PubMedGoogle Scholar

Kiser RS, Cohen HM, Freedenfeld RN et al. (2001) Olanzapine for the treatment of fibromyalgia symptoms. J Pain Symptom Manage 22: 704–708PubMedCrossRefGoogle Scholar

McCleane G (2000) Does intravenous lidocaine reduce fibromyalgia pain? A randomized, double-blind, placebo controlled cross-over study. Pain Clin 12: 181–185CrossRefGoogle Scholar

McKenzie R, O’Fallon A, Dale J et al. (1998) Low-dose hydrocortisone for treatment of chronic fatigue syndrome: a randomized controlled trial. JAMA 280: 1061–1066PubMedCrossRefGoogle Scholar

Moldofsky H, Lue FA, Mously C et al. (1996) The effect of zolpidem in patients with fibromyalgia: a dose ranging, double blind, placebo con-trolled, modified crossover study. J Rheumatol 23: 529–533PubMedGoogle Scholar

Müller A, Hartmann M, Eich W (2000) Health care utilization in patients with fibromyalgia syndrome (FMS). Schmerz 14: 77–83PubMedCrossRefGoogle Scholar

Nagaoka S, Ohno M, Sekiguchi A (2004) An open-label clinical trial of milnacipran in fibromyalgia syndrome with co-morbid depressive symptoms. Psychiatry Clin Psycho 8: 47–51Google Scholar

Nørregaard J, Volkmann H, Danneskiold-Samsoe B (1995) A randomized controlled trial of citalopram in the treatment of fibromyalgia. Pain 61: 445–449PubMedCrossRefGoogle Scholar

O’Malley PG, Balden E, Tomkins G et al. (2000) Treatment of fibromyalgia with antidepressants: a meta-analysis. J Gen Intern Med 15: 659–666CrossRefGoogle Scholar

Offenbaecher M, Waltz M, Schoeps P (2000) Validation of a German version of the Fibromyalgia Impact Questionnaire (FIQ-G). J Rheumatol 27: 1984–1988PubMedGoogle Scholar

Olin R, Klein R, Berg PA (1998) A randomised double-blind 16-week study of ritanserin in fibromyalgia syndrome: clinical outcome and analysis of autoantibodies to serotonin, gangliosides and phospholipids. Clin Rheumatol 17: 89–94PubMedCrossRefGoogle Scholar

Özerbil O, Okudan N, Gökbel H et al. (2006) Comparison of the effects of two antidepressants on exercise performance of the female patients with fibromyalgia. Clin Rheumatol 25: 495–497PubMedCrossRefGoogle Scholar

Pattrick M, Swannell A, Doherty M (1993) Chlormezanone in primary fibromyalgia syn-drome: a double blind placebo controlled study. Br J Rheumatol 32: 55–58PubMedCrossRefGoogle Scholar

Posner IA (1994) Treatment of fibromyalgia syndrome with intravenous lidocaine: a prospective, randomized pilot study. J Musculoskelet Pain 2: 55–65CrossRefGoogle Scholar

Quijada-Carrera J, Valenzuela-Castano A, Povedano-Gomez J et al. (1996) Comparison of tenoxicam and bromazepan in the treatment of fi-bromyalgia: a randomized, double-blind, placebo-controlled trial. Pain Pract 65: 221–225Google Scholar

Quimby LG, Gratwick GM, Whitney CD et al. (1989) A randomized trial of cyclobenzaprine for the treatment of fibromyalgia. J Rheumatol 19 [suppl]: 140–143Google Scholar

Raphael JH, Southall JL, Treharne GJ et al. (2002) Efficacy and adverse effects of intravenous lignocaine therapy in fibromyalgia syndrome. BMC Musculoskelet Disord 3: 21PubMedCrossRefGoogle Scholar

Reynolds WJ, Moldofsky H, Saskin P et al. (1991) The effects of cyclobenzaprine on sleep physiology and symptoms in patients with fibromyalgia. J Rheumatol 18: 452–454PubMedGoogle Scholar

Rico-Villademoros F, Hidalgo J, Dominguez I et al. (2005) Atypical antipsychotics in the treatment of fibromyalgia: a case series with olanzapine. Prog Neuropsychopharmacol Biol Psychiatry 29: 161–164PubMedCrossRefGoogle Scholar

Robinson RL, Jones ML (2006) In search of pharmacoeconomic evaluations for fibromyalgia treatments: a review. Expert Opin Pharmacother 7: 1027–1039PubMedCrossRefGoogle Scholar

Russell IJ, Fletcher EM, Michalek JE et al. (1991) Related articles, treatment of primary fibrositis/fibromyalgia syndrome with ibuprofen and alprazolam. A double-blind, placebo-controlled study. Arthritis Rheum 34: 552–560PubMedCrossRefGoogle Scholar

Russell IJ, Kamin M, Bennett RM et al. (2000) Efficacy of tramadol in treatment of pain in fibromyalgia. J Clin Rheumatol 6: 250–257CrossRefPubMedGoogle Scholar

Samborski W, Lezanska-Szpera M, Rybakowski JK (2004) Open trial of mirtazapine in patients with fibromyalgia. Pharmacopsychiatry 37: 168–170PubMedCrossRefGoogle Scholar

Santandrea S, Montrone F, Sarzi-Puttini P et al. (1993) A double-blind crossover study of two cyclobenzaprine regimens in primary fibromyalgia syndrome. J Int Med Res 21: 74–80PubMedGoogle Scholar

Sayar K, Aksu G, Ak I et al. (2003) Venlafaxine treatment of fibromyalgia. Ann Pharmacother 37: 1561–1565PubMedCrossRefGoogle Scholar

Scharf MB, Baumann M, Berkowitz DV (2003) The effects of sodium oxybate on clinical symptoms and sleep patterns in patients with fibromyalgia. J Rheumatol 30: 1070–1074PubMedGoogle Scholar

Scudds RA, McCain GA, Rollman GB et al. (1989) Improvements in pain responsiveness in patients with fibrositis after successful treatment with amitriptyline. J Rheumatol 19 [suppl]: 98–103Google Scholar

Şencan S, Ak S, Karan A et al. (2004) A study to compare the therapeutic efficacy of aerobic exercise and paroxetine in fibromyalgia syndrome. J Back Musculoskelet Rehabil 17: 57–61Google Scholar

Sörensen J, Bengtsson A, Ahlner J et al. (1997) Related articles, Fibromyalgia – are there different mechanisms in the processing of pain? A double blind crossover comparison of analgesic drugs. J Rheumatol 24: 1615–1621PubMedGoogle Scholar

Sörensen J, Bengtsson A, Backman E et al. (1995) Pain analysis in patients with fibromyalgia. Effects of intravenous morphine, lidocaine, and ketamine. Scand J Rheumatol 24: 360–365PubMedCrossRefGoogle Scholar

Späth M, Stratz T, Neeck G et al. (2004) Related articles, efficacy and tolerability of intravenous tropisetron in the treatment of fibromyalgia. Scand J Rheumatol 33: 267–270PubMedCrossRefGoogle Scholar

Stoll LA (2000) Fibromyalgia symptoms relieved by flupirtine: an open-label case series. Psychosomatics 41: 371–372PubMedCrossRefGoogle Scholar

Tavoni A, Vitali C, Bombardieri S et al. (1987) Evaluation of S-adenosylmethionine in primary fibromyalgia. A double-blind crossover study. Am J Med 83: 107–110PubMedCrossRefGoogle Scholar

Tofferi JK, Jackson JL, O’Malley PG (2004) Treatment of fibromyalgia with cyclobenzaprine: a meta-analysis. Arthritis Rheum 51: 9–13PubMedCrossRefGoogle Scholar

Üçeyler N, Häuser W, Sommer C (2008) A systematic review of the effectiveness of treatment with antidepressants in fibromyalgia syndrome. Arthritis Care Res, in pressGoogle Scholar

Vitton O, Gendreau M, Gendreau J et al. (2004) A double-blind placebo-controlled trial of milnacipran in the treatment of fibromyalgia. Hum Psychopharmacol 19(1): 27–35CrossRefGoogle Scholar

Wolfe F, Cathey MA, Hawley DJ (1994) A double-blind placebo controlled trial of fluoxetine in fibromyalgia. Scand J Rheumatol 23: 255–259PubMedCrossRefGoogle Scholar

Wörz R (1991) Flupirtin bei chronischen myofasziellen Schmerzzuständen. Fortschr Med 109: 158–160PubMedGoogle Scholar

Yavuzer G, Küçükdeveci A, Arasli T et al. (1998) Moclobemid treatment in primary fibromyalgia syndrome. Eur J Phys Med Rehabil 8: 35–38Google Scholar

Yunus MB, AT M, Aldağ JC (1989) Short term effects of ibuprofen in primary fibromyalgia syndrome: a double blind, placebo controlled trial. J Rheumatol 16: 527–532PubMedGoogle Scholar